Personalized follow-up visit system for GHD patients

Abstract

The invention relates to a follow-up visit system, in particular to a personalized follow-up visit system for GHD patients. The invention designs a personalized follow-up visit system for a patient suffering from growth hormone deficiency (GHD), and the system aims at improving the treatment effect and life quality of the patient suffering from GHD through comprehensive and accurate information collection, evaluation, follow-up visit plan generation and health education.

Description

Technical Field

[0001] The present invention relates to a follow-up system, in particular to a personalized follow-up system for GHD patients. Background Art

[0002] Growth hormone deficiency (GHD) is a disease of particular concern in the field of pediatric endocrinology. Due to insufficient growth hormone secretion, patients suffer from short stature, significantly below the average height of healthy children of the same age. GHD is primarily treated with long-term hormone replacement therapy, typically lasting one to two years. During this period, patients require regular follow-up visits to monitor treatment effectiveness and adjust their treatment plans. However, traditional follow-up models have significant challenges, such as long follow-up intervals (typically three months) and a lack of personalized adjustments to address individual patient differences. This model often fails to promptly identify and address issues that arise during treatment, thus compromising treatment effectiveness.

[0003] In addition to drug treatment, GHD patients also need complex health education during the treatment process, including nutrition, exercise, sleep and other aspects. These factors have a significant impact on the treatment effect, but the complexity of the disease and the response to treatment vary from patient to patient. For example, some patients may experience slow growth and development, drug side effects and other problems during follow-up, and the treatment plan needs to be adjusted in time. In addition, children and their families often have concerns and anxieties about the treatment effect and side effects during the treatment process, which not only affects the patient's drug compliance, but may also increase the loss rate and increase the psychological burden. Therefore, follow-up management and health education for GHD patients need to be more personalized and refined.

[0004] Existing follow-up systems mainly focus on data collection and basic follow-up plan formulation, but lack the ability to customize and dynamically adjust according to the characteristics of GHD patients. Follow-up management of GHD patients not only needs to consider the patient's growth and development indicators such as height and weight, but also requires a comprehensive assessment of the patient's medication status, test results, and mastery of lifestyle intervention measures. Traditional follow-up systems are often unable to achieve comprehensive analysis and dynamic adjustment of this information, resulting in inaccurate follow-up plans and lack of targeted health education content. Therefore, it is particularly important to develop a follow-up system that can comprehensively consider the individual differences of GHD patients, dynamically adjust follow-up plans, and provide personalized health education.

[0005] Although some patents focus on personalized follow-up for common chronic diseases, such as CN 118072915A, these solutions are not specifically designed to address the specific characteristics and issues of GHD patients. The follow-up management and health education needs of GHD patients are unique and require comprehensive consideration of multiple aspects, including the patient's growth and development, drug response, and psychological status. Therefore, it is necessary to develop a personalized follow-up system specifically for GHD patients. By utilizing advanced information technologies such as big data analysis and artificial intelligence, it is possible to personalize and dynamically adjust follow-up plans and accurately deliver health education content, thereby improving the treatment effect and quality of life of GHD patients. Summary of the Invention

[0006] This paper designs a personalized follow-up system for patients with growth hormone deficiency (GHD). The system aims to improve the treatment effect and quality of life of GHD patients through comprehensive and accurate information collection, evaluation, follow-up plan generation and health education.

[0007] Specifically, the present invention provides a personalized follow-up system for GHD patients, which includes: The information collection module is used to collect the patient's height and weight data at each follow-up node, record medication status, and import test results; An evaluation module, which analyzes and evaluates the information collected by the information collection module according to preset evaluation criteria; A follow-up plan generation module generates a personalized follow-up plan based on the evaluation results of the evaluation module; The health education module stores and pushes health education content for GHD patients.

[0008] Specifically, the information collection module further includes: Height and weight measurement equipment interface, used to receive height and weight data obtained through professional measurement equipment; Doctor input interface, used by doctors to manually enter patients' medication information, including drug name, dosage, frequency of use, etc. The test result import interface is used to connect with the hospital's test system to automatically import or manually upload test results.

[0009] Specifically, the evaluation module includes: The height and weight related assessment submodule is used to assess the patient's height growth rate and weight gain; Medication use assessment submodule, used to evaluate the efficacy and safety of drugs; The test result evaluation submodule is used to comprehensively evaluate endocrine indicators, bone age and nutrition-related indicators.

[0010] Specifically, the height and weight related assessment submodule evaluates the patient's growth and development by calculating the height growth rate and weight growth rate and comparing them with the preset normal range.

[0011] Specifically, the medication status evaluation submodule evaluates the efficacy and safety of drugs by monitoring changes in specific test indicators, and adjusts the drug dosage or changes the type of drug based on the evaluation results.

[0012] Specifically, the test result evaluation submodule evaluates the patient's growth and development status and potential health problems by monitoring endocrine hormone levels, bone age and nutrition-related indicators.

[0013] Specifically, the follow-up plan generation module dynamically adjusts the follow-up interval and examination items according to the evaluation results. For patients with slow growth and development, signs of drug side effects or abnormal test results, the follow-up interval is shortened and corresponding examination items are added.

[0014] Specifically, the health education module includes health education content in terms of diet, sleep and exercise, and dynamically pushes corresponding health education content according to the patient's follow-up status classification and follow-up stage.

[0015] Specifically, it also includes a user interaction module for receiving user feedback and adjusting the follow-up plan and health education content based on the feedback.

[0016] Specifically, the system supports cross-platform integration and data sharing, and can achieve seamless connection with the hospital's existing information systems (such as HIS, LIS, etc.), thereby improving the continuity of medical services and data utilization efficiency.

[0017] Compared with the prior art, the present invention has the following technical effects: First, this invention addresses the primary technical challenge facing GHD patients—the lack of personalization and timeliness of traditional follow-up models—by proposing a personalized follow-up system. This system allows doctors to accurately assess patients' status based on their real-time height, weight, medication status, and test results, allowing them to promptly adjust follow-up plans and treatment plans. This significantly improves the accuracy and timeliness of follow-up visits, ensuring that patient issues are promptly identified and addressed, and effectively enhancing treatment outcomes for GHD patients.

[0018] Secondly, the personalized follow-up system of this invention can generate customized follow-up plans and health education content based on individual patient differences and disease dynamics. This personalized service not only meets the patient's specific needs but also enhances treatment compliance, helps patients better understand and manage their condition, and thus improves their quality of life.

[0019] Furthermore, by seamlessly integrating with existing hospital information systems, the system enables cross-platform data integration and sharing. This not only avoids duplicate data entry and querying, improving the consistency and efficiency of medical services, but also enables doctors to more easily access comprehensive patient information, providing strong support for precision medicine.

[0020] Finally, the system also prioritizes patient health education, dynamically delivering relevant diet, sleep, and exercise recommendations to help patients establish a healthy lifestyle and enhance their self-management abilities. This comprehensive health management strategy helps patients maintain a healthy physical and mental state during treatment, further facilitating recovery. DETAILED DESCRIPTION

[0021] The present invention will be further described in detail below with reference to specific embodiments.

[0022] Example 1 A personalized follow-up system for GHD patients includes: an information collection module, an evaluation module, a follow-up plan generation module and a health education module.

[0023] Information collection module Used to collect the patient's height and weight data at each follow-up node, record medication status and enter test results.

[0024] Height and weight data are obtained through professional measuring equipment and transmitted to the system database.

[0025] Medication information includes drug name, dosage, frequency of use, and other information, which is manually entered by the doctor.

[0026] The test results can be automatically imported or manually uploaded through the interface with the hospital's testing system, such as blood hormone level test results, bone age test reports, etc.

[0027] Evaluation Module Based on the collected information, analysis and evaluation are carried out according to the preset evaluation criteria.

[0028] Assessment criteria are based on extensive clinical data and medical research. For example, Body Mass Index (BMI) is calculated using height and weight data using the formula: BMI = Weight (kg) ÷ Height² (m²). A patient's nutritional status is determined based on the normal BMI range for different age groups.

[0029] Combined with medication conditions and test results, determine whether the effect of drug treatment has achieved the expected results. For example, by comparing the rate of change of specific hormone levels before and after treatment, the effectiveness of drugs in regulating growth and development-related hormones can be evaluated.

[0030] The evaluation module includes: a height and weight related evaluation submodule, a medication status evaluation submodule, and a test result evaluation submodule.

[0031] The height and weight related assessment submodule can realize height growth rate assessment and weight gain assessment: Height growth rate assessment The height growth value of the patient between adjacent follow-up nodes was calculated, that is, the height at the current follow-up minus the height at the previous follow-up, to obtain the height growth value (ΔH).

[0032] Compare and assess the patient's height growth rate based on the normal range for their age. For example, for children aged 3 to 6, the normal annual growth rate is approximately 5 to 8 cm; for children aged 6 to 10, it's approximately 4 to 6 cm; for adolescents aged 10 to 14, it's approximately 5 to 7 cm (boys) and 4 to 6 cm (girls). If a patient's height growth value falls below a certain percentage (e.g., 70%) of the lower limit of the normal range for the same age group, it is considered slow growth, requiring further analysis and consideration of adjusting the treatment plan or adding additional examinations.

[0033] At the same time, calculate the trend of height growth rate. Using height growth values ​​at multiple consecutive follow-up points, use linear regression or other appropriate trend analysis methods to determine whether the height growth rate is stabilizing, increasing, or decreasing. If a downward trend is observed, even if the current height growth value is still within the normal range, it warrants attention and in-depth evaluation.

[0034] Weight gain assessment Similar to the height growth assessment, the weight gain value (ΔW) between adjacent follow-up nodes was calculated.

[0035] Refer to weight growth curves for patients of different ages and genders to determine the normal weight gain range. For example, during infancy (0-1 year old), weight gain is rapid, averaging approximately 0.6-0.8 kg per month in the first six months and 0.3-0.5 kg per month in the second six months. During early childhood (1-3 years old), weight gain is approximately 2-3 kg per year. If weight gain exceeds the upper limit of the normal range or falls below the lower limit by a certain percentage (e.g., 80%), it is labeled as abnormal weight gain, which may indicate overnutrition, malnutrition, or other underlying medical conditions affecting growth and development. Further evaluation of the patient's dietary intake and metabolic indicators is necessary.

[0036] Analyze changes in body mass index (BMI) in conjunction with height growth. In addition to the previously mentioned BMI calculation formula (BMI = weight (kg) ÷ height² (m²)), it's also important to monitor BMI trends at different follow-up points and their relationship to the normal BMI percentile curve for the same age and gender. If a patient's BMI gradually shifts from the normal range toward overweight or obesity, and their height growth rate doesn't increase or even slows, they may have endocrine disorders or unhealthy lifestyle factors that are impacting growth and development, such as hypothyroidism leading to a lower basal metabolic rate or insufficient physical activity.

[0037] Medication use assessment submodule The medication status evaluation submodule can realize drug efficacy evaluation and drug safety evaluation: Drug efficacy evaluation Specific test indicators or clinical symptom improvement criteria are set based on the expected therapeutic effect of the medication being used. For example, for patients with dwarfism treated with growth hormone, changes in serum insulin-like growth factor-1 (IGF-1) levels are monitored. Initially, if IGF-1 levels fail to rise above the lower limit of the normal age-related reference range at two consecutive follow-up visits (three months apart), or if the increase is lower than expected (e.g., an expected 50% increase but an actual increase of less than 30%), this indicates that growth hormone treatment is ineffective and may require adjustment of the drug dosage, switching drug brands, or further evaluation of factors such as growth hormone resistance.

[0038] For drugs used to treat precocious puberty, such as gonadotropin-releasing hormone analogs (GnRHa), the suppression of sexual development is observed. This is accomplished by regularly checking indicators such as the degree of breast development (e.g., Tanner staging), testicular volume (for boys), and bone age progression. If sexual development continues to progress during treatment, such as continued breast enlargement and no significant slowing of bone age growth (normally, the rate of bone age growth should be significantly reduced after GnRHa treatment, with no more than 0.5 years of growth per year), this indicates that the drug's inhibitory effect on the gonadal axis is incomplete, and the treatment plan needs to be re-evaluated. This may include increasing the drug dosage, combining other medications, or screening for secondary causes of precocious puberty, such as tumors.

[0039] Drug safety assessment Monitor patients for changes in indicators related to adverse reactions or side effects during medication. For example, some drugs may affect liver and kidney function, so serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (Cr), blood urea nitrogen (BUN) and other indicators should be checked at each follow-up. If these indicators exceed a certain multiple of the upper limit of the normal range (such as ALT or AST exceeds 2 times the upper limit of normal), and other factors that may cause abnormal liver and kidney function (such as infection, other underlying diseases, etc.) are excluded, it indicates that the drug may have the risk of liver and kidney damage, and it is necessary to consider adjusting the drug dosage, suspending the drug, or replacing it with an alternative drug with less impact on liver and kidney function, and closely monitor the recovery of liver and kidney function. For drugs that may affect the blood system, such as certain chemotherapy drugs used to treat diseases such as childhood leukemia that affect growth and development, check blood routine indicators, including white blood cell count (WBC), red blood cell count (RBC), platelet count (PLT), hemoglobin (Hb), etc. If leukopenia occurs (WBC < 4.0×10 9 / L), thrombocytopenia (PLT < 100×10 9 / L) or anemia (Hb below the lower limit of the normal range for people of the same age and gender), and there is a correlation with the duration of drug use, it is necessary to evaluate the degree of drug toxicity to the blood system and take appropriate supportive treatment measures, such as the use of white blood cell-raising drugs and blood transfusions. The decision on whether to continue the original treatment plan, adjust the dose, or stop the drug should be made based on the recovery of blood system indicators.

[0040] The test result evaluation submodule can realize endocrine index evaluation, bone age evaluation and nutrition-related index evaluation. In addition to the endocrine indicators related to drug efficacy mentioned above (such as IGF-1 in growth hormone treatment, sex hormone levels in the treatment of precocious puberty, etc.), the impact of other endocrine hormone levels on growth and development is also comprehensively evaluated. For example, thyroid hormones (including T3, T4, and TSH) are crucial for children's growth and development, especially the development of the nervous system. If hypothyroidism occurs, T3 and T4 levels decrease, and TSH increases, the patient may experience symptoms such as growth retardation and intellectual disability. During follow-up, if thyroid hormone abnormalities are found, even if the patient's main diagnosis is not a growth and development disorder related to thyroid disease, the impact of thyroid dysfunction on overall growth and development must be considered. Endocrinology specialist consultation may be required, thyroid hormone supplementation treatment, and observation of changes in growth and development indicators after supplementation treatment.

[0041] Test adrenal cortical hormone levels, such as cortisol. Both hyperfunction and hypofunction of the adrenal cortex may affect growth and development. For example, hyperfunction of the adrenal cortex may lead to accelerated growth but premature skeletal age closure, resulting in impaired height. Hypofunction of the adrenal cortex may cause symptoms such as growth retardation and fatigue. Functional tests such as monitoring the circadian rhythm of cortisol secretion (such as cortisol levels at different times of the day, afternoon, and night) and ACTH stimulation tests can assess adrenal cortical function. If abnormalities are found, further investigation is conducted to identify the cause of the adrenal disease, and treatment plans can be adjusted based on the specific circumstances, such as supplementation of adrenal cortex hormones or treatment of primary diseases such as adrenal tumors.

[0042] Bone age assessment Bone age is determined using standard bone age determination methods (such as the Greulich-Pyle or Tanner-Whitehouse methods) with left wrist X-rays obtained at each follow-up visit. The difference between the patient's chronological age and bone age is compared to assess growth maturity and remaining growth potential. Normally, the difference between bone age and chronological age should be within ±1 year. If the bone age is significantly advanced (e.g., bone age is more than 2 years older than chronological age), it suggests a tendency toward precocious puberty or other factors leading to accelerated bone development, which may affect final height. Further analysis is needed, such as screening for causes of precocious puberty such as intracranial tumors or adrenal tumors, or assessing the impact of factors such as overnutrition and exposure to environmental endocrine disruptors on bone age. Treatment strategies can be adjusted accordingly, such as strengthening treatment and control of precocious puberty, adjusting dietary structure, and reducing exposure to environmental endocrine disruptors. On the contrary, if the bone age is delayed (bone age is more than 2 years younger than actual age), in addition to considering common causes such as growth hormone deficiency, it is also necessary to check for chromosomal abnormalities (such as Turner syndrome), chronic diseases (such as congenital heart disease, chronic kidney disease, etc. that affect growth and development) and other factors, treat the causes, and closely observe the progression of bone age and changes in growth and development indicators.

[0043] Assessment of nutrition-related indicators In addition to indirectly reflecting a patient's nutritional status through height, weight, and BMI, specific nutritional indicators are also measured. For example, serum vitamin D levels play a key role in calcium and phosphorus metabolism and bone development. Vitamin D deficiency can lead to rickets, affecting children's growth and development, manifesting as skeletal deformities and growth retardation. Normal serum 25-hydroxyvitamin D levels should be between 30 and 100 ng / mL. A level below 20 ng / mL indicates vitamin D deficiency and requires vitamin D supplementation. The increase in serum vitamin D levels and improvement in bone development markers (such as serum calcium, phosphorus, and alkaline phosphatase) after supplementation should be monitored.

[0044] Measure levels of trace elements such as serum ferritin, serum zinc, and serum copper, as these trace elements are essential for maintaining normal physiological functions and growth and development. For example, iron deficiency can lead to iron-deficiency anemia, which can affect children's growth and intellectual development, manifesting as pale complexion, fatigue, and difficulty concentrating. Serum ferritin is a sensitive indicator of iron storage in the body. The normal range varies by age and gender. Generally, children's serum ferritin levels should be between 30 and 150 ng / mL. A level below 15 ng / mL indicates iron deficiency and requires iron supplementation. Regular blood tests and serum ferritin levels should be reviewed to monitor the correction of anemia and the restoration of iron stores. Zinc deficiency can affect children's appetite, growth, development, and immune function. The normal range for serum zinc is approximately 70 to 150 μg / dL. A level below 65 μg / dL may indicate zinc deficiency, and zinc supplementation should be administered. The patient should also be monitored for improvement in appetite and growth rate after treatment. Copper deficiency is relatively rare, but it can also affect bone development and nervous system function. The normal range of serum copper is approximately 70-140 μg / dL. If abnormal serum copper levels are found, further investigation of the cause of copper deficiency (such as congenital copper metabolism disorders, long-term parenteral nutrition without sufficient copper supplementation, etc.) is required, and appropriate treatment and monitoring should be carried out.

[0045] Through the above multi-dimensional, comprehensive and systematic evaluation criteria, the evaluation module can accurately and objectively analyze the situation of patients with growth and development diseases at each follow-up node, providing a scientific basis for subsequent follow-up plan generation, treatment plan adjustment and health education content delivery, thereby achieving refined management and personalized treatment of patients with growth and development diseases, and improving treatment effects and patients' quality of life.

[0046] Follow-up plan generation module Generate a personalized follow-up plan based on the assessment results.

[0047] If the patient's growth and development indicators are normal, the medication is effective, and the test results are stable, the next follow-up interval can be set at 3 months; if there are slow growth and development, signs of drug side effects, or abnormal test results, the follow-up interval can be shortened to 1-2 months and the subsequent examination items can be adjusted.

[0048] Follow-up intervals are calculated as follows: set up Indicates the height growth rate (unit: cm / month), represents the height at this follow-up (unit: cm), is the height at the last follow-up (unit: cm), is the time interval between two follow-up visits (unit: month, here it is 3 months), then: set up is the height growth rate assessment coefficient. The lower limit of normal height growth rate for a specific age stage is ,if: set up Indicates the weight gain rate (unit: kg / month), represents the body weight at this follow-up visit (unit: kilogram), represents the weight at the last follow-up visit (unit: kilogram), then: set up is the weight growth rate assessment coefficient. The upper and lower limits of normal weight growth rate for a specific age stage are and ,if: set up The drug efficacy evaluation value (for example, for a drug to treat a specific disease, it can be measured by the degree of improvement of relevant test indicators or the ratio to the expected efficacy). The initial expected efficacy value is The corresponding efficacy values ​​of the relevant indicators observed during this follow-up were ,but: set up The drug safety assessment value is measured by the degree to which the monitored adverse reactions or side effects related indicators exceed the normal range, and the upper limit of the normal range is set as The index measurement value at this follow-up was , if only a single key indicator is considered (it can be extended to a comprehensive evaluation of multiple indicators according to actual conditions), then: set up For the follow-up interval (unit: month), you can set a basic follow-up interval (e.g. 3 months), and adjusted according to height, weight, drug efficacy and safety evaluation coefficients, and the adjustment coefficients are (These coefficients can be determined based on a large amount of clinical data and experience. For example, when height growth is slow, weight gain is abnormal, drug efficacy is poor, or safety issues arise, the corresponding coefficients can shorten the follow-up interval.) Then: For example, if the height growth rate estimation coefficient is determined hour, (i.e. when height growth is slow, the follow-up interval may be shortened to about 1.5 times the original one); when the weight growth rate assessment coefficient or hour, Similar rules can be used to dynamically adjust the follow-up interval based on the specific circumstances of each follow-up visit of the patient.

[0049] Health Education Module Store and push health education content for patients with growth and developmental diseases.

[0050] Diet: Patients are advised to ensure adequate daily protein intake, including high-quality protein sources such as milk, eggs, and lean meat. At the same time, they should limit excessive intake of sugar and fat, and consume plenty of fresh fruits and vegetables to supplement vitamins and minerals. The recommended daily protein intake (g) can be calculated based on the patient's age and weight using the formula: Protein intake = age × weight (kg) × 0.8 (applicable to specific age groups).

[0051] Sleep: Emphasize the importance of adequate sleep for growth and development. It is recommended that patients ensure 8-10 hours of sleep every night, establish a regular schedule, and avoid using electronic devices before going to bed to improve sleep quality.

[0052] In terms of exercise: patients are encouraged to do moderate aerobic exercise, such as skipping rope, basketball, swimming, etc., at least 4 times a week, each exercise time should be more than 30 minutes, and the exercise intensity should be enough to make them sweat slightly, to promote bone growth and muscle development.

[0053] Example 2 System Workflow During a patient's first visit, the doctor enters their basic information, including name, age, gender, and medical history, into the system and initiates a follow-up plan. At the follow-up point, the information collection module collects the patient's height, weight, medication status, and test results.

[0054] The assessment module processes and evaluates the collected information, calculating relevant data indicators (such as BMI and hormone level change rate), and comparing them with preset standards. The follow-up plan generation module determines the next follow-up interval and examination items based on the assessment results. Meanwhile, the health education module pushes relevant health education content to patients. Based on the system-generated follow-up plan and assessment results, doctors adjust the patient's treatment plan (such as adjusting medication dosage or changing medication type) and record them in the system.

[0055] The above is a preferred embodiment of the present invention. For ordinary technicians in this field, based on the teachings of the present invention, without departing from the principles and spirit of the present invention, changes, modifications, substitutions and variations made to the implementation methods are still within the scope of protection of the present invention.

Claims

1. A personalized follow-up system for GHD patients, characterized by: include: The information collection module is used to collect the patient's height and weight data at each follow-up node, record medication status, and import test results; An evaluation module, which analyzes and evaluates the information collected by the information collection module according to preset evaluation criteria; A follow-up plan generation module generates a personalized follow-up plan based on the evaluation results of the evaluation module; The health education module stores and pushes health education content for GHD patients.

2. The system according to claim 1, wherein: The information collection module further includes: Height and weight measurement equipment interface, used to receive height and weight data obtained through professional measurement equipment; Doctor input interface, used by doctors to manually enter patients' medication information, including drug name, dosage, frequency of use, etc. The test result import interface is used to connect with the hospital's test system to automatically import or manually upload test results.

3. The system according to claim 1, wherein: The evaluation module includes: The height and weight related assessment submodule is used to assess the patient's height growth rate and weight gain; Medication use assessment submodule, used to evaluate the efficacy and safety of drugs; The test result evaluation submodule is used to comprehensively evaluate endocrine indicators, bone age and nutrition-related indicators.

4. The system according to claim 3, characterized in that The height and weight related assessment submodule evaluates the patient's growth and development by calculating the height growth rate and weight growth rate and comparing them with the preset normal range.

5. The system according to claim 3, wherein: The medication status assessment submodule evaluates the efficacy and safety of drugs by monitoring changes in specific test indicators, and adjusts drug dosages or changes drug types based on the assessment results.

6. The system according to claim 3, wherein: The test result evaluation submodule evaluates the patient's growth and development status and potential health problems by monitoring endocrine hormone levels, bone age and nutrition-related indicators.

7. The system according to claim 1, wherein: The follow-up plan generation module dynamically adjusts the follow-up interval and examination items according to the evaluation results. For patients with slow growth and development, signs of drug side effects or abnormal test results, the follow-up interval is shortened and corresponding examination items are added.

8. The system according to claim 1, wherein: The health education module includes health education content in terms of diet, sleep and exercise, and dynamically pushes corresponding health education content according to the patient's follow-up status classification and follow-up stage.

9. The system according to claim 1, wherein: It also includes a user interaction module for receiving user feedback and adjusting the follow-up plan and health education content based on the feedback.

10. The system according to any one of claims 1 to 9, characterized in that The system supports cross-platform integration and data sharing, and can achieve seamless connection with the hospital's existing information system, thereby improving the continuity of medical services and data utilization efficiency. The hospital's existing information system includes HIS or LIS.

Images